RxDoctor Payments Data

Robert Malamis, MD

Internal Medicine · Atlanta, GANPI 1053323824

Payments from drug & device makers

$296in general payments, 2019–2025

Across 21 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$191
  • Amgen$20
  • GSK$19
  • Kvk-tech, Inc.$18
  • Pfizer$18
  • Gilead$16
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company15$191
Amgen1$20
GSK1$19
Kvk-tech, Inc.1$18
Pfizer1$18
Gilead1$16
Johnson & Johnson1$14

How this compares

$296 in reported general payments places this provider in the 45th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$181,597
Medicare patients
264
Services billed
3,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen47$210,941
BiktarvyBictegrav/Emtricit/Tenofov Ala29$152,239
TivicayDolutegravir Sodium38$85,454
PrezcobixDarunavir/Cobicistat30$73,530
OzempicSemaglutide52$56,148
EliquisApixaban58$53,303
TriumeqAbacavir/Dolutegravir/Lamivudi12$44,996
XareltoRivaroxaban27$33,621
DescovyEmtricitabine/Tenofov Alafenam14$31,325
JanuviaSitagliptin Phosphate28$20,838
MounjaroTirzepatide19$19,582
EdurantRilpivirine Hcl12$17,494
FarxigaDapagliflozin Propanediol17$16,383
ArexvyRsvpref3 Antigen/As01e/Pf42$12,752
SynthroidLevothyroxine Sodium61$6,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$16$394,50490 claims
Viiv Healthcare CompanyTivicay, Triumeq$191$130,45150 claims
Johnson & JohnsonPrezcobix, Xarelto$14$107,15157 claims
PfizerEliquis, Paxlovid$18$57,53983 claims
GSKArexvy, Arnuity Ellipta$19$17,48854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →